Table 3.
Demographic, preoperative, and intraoperative data of patients dichotomized according to the optimal cut-off value of PNI before and after propensity score matching
| Variable | Before propensity score matching | After propensity score matching | ||||||
|---|---|---|---|---|---|---|---|---|
| PNI > 45 [n = 518] | PNI ≤ 45 [n = 304] | SMD | p-Value | PNI > 45 [n = 221] | PNI ≤ 45 [n = 221] | SMD | p-Value | |
| Female sex | 66 (12.7) | 65 (21.4) | 0.210 | 0.002 | 40 (18.1) | 45 (20.4) | 0.055 | 0.625 |
| Age, years | 62.8 ± 10.1 | 66.5 ± 9.7 | 0.389 | < 0.001 | 66.0 ± 10.0 | 66.0 ± 10.0 | 0.004 | 0.964 |
| Body mass index, kg/m2 | 24.7 ± 3.1 | 23.2 ± 3.1 | −0.492 | < 0.001 | 23.8 ± 2.7 | 23.6 ± 3.0 | −0.065 | 0.435 |
| ASA Physical Status | 0.126 | 0.065 | 0.013 | > 0.999 | ||||
| ≤ 2 | 469 (90.5) | 262 (86.2) | 194 (87.8) | 193 (87.3) | ||||
| 3 | 49 (9.5) | 42 (13.8) | 27 (12.2) | 28 (12.7) | ||||
| Diabetes mellitus | 96 (18.5) | 56 (18.4) | −0.003 | > 0.999 | 47 (21.3) | 45 (20.4) | −0.023 | 0.905 |
| Hypertension | 205 (39.6) | 126 (41.4) | 0.038 | 0.607 | 94 (42.5) | 94 (42.5) | < 0.001 | > 0.999 |
| Coronary artery disease | 24 (4.6) | 16 (5.3) | 0.028 | 0.738 | 12 (5.4) | 12 (5.4) | < 0.001 | > 0.999 |
| Cerebrovascular disease | 16 (3.1) | 14 (4.6) | 0.072 | 0.335 | 10 (4.5) | 8 (3.6) | −0.043 | 0.804 |
| COPD | 20 (3.9) | 9 (3.0) | −0.053 | 0.562 | 6 (2.7) | 5 (2.3) | −0.027 | > 0.999 |
| Smoking | −0.154 | 0.034 | 0.054 | 0.651 | ||||
| Non/Ex-smoker | 316 (61.0) | 162 (53.3) | 105 (47.5) | 99 (44.8) | ||||
| Current smoker | 202 (39.0) | 142 (46.7) | 116 (52.5) | 122 (55.2) | ||||
| Tumor stage | 0.101 | 0.171 | 0.098 | 0.368 | ||||
| <3 | 382 (73.7) | 210 (69.1) | 158 (71.5) | 148 (67.0) | ||||
| ≥3 | 136 (26.3) | 94 (30.9) | 63 (28.5) | 73 (33.0) | ||||
| Tumor grade | 0.295 | 0.009 | −0.071 | 0.727 | ||||
| 2 | 28 (5.4) | 5 (1.6) | 3 (1.4) | 5 (2.3) | ||||
| 3 | 490 (94.6) | 299 (98.4) | 218 (98.6) | 216 (97.7) | ||||
| Neoadjuvant chemotherapy | 76 (14.7) | 87 (28.6) | 0.308 | < 0.001 | 54 (24.4) | 63 (28.5) | 0.090 | 0.374 |
| Hemoglobin, g/dL | 13.0 ± 1.7 | 11.0 ± 1.7 | − 1.157 | < 0.001 | 11.7 ± 1.5 | 11.5 ± 1.6 | −0.123 | 0.210 |
| Creatinine, mg/dL | 1.0 ± 0.8 | 1.2 ± 1.0 | 0.110 | 0.090 | 1.1 ± 0.9 | 1.0 ± 0.4 | −0.087 | 0.188 |
| Operation duration, min | 440.0 ± 103.3 | 413.1 ± 100.5 | −0.268 | < 0.001 | 423.1 ± 103.2 | 419.8 ± 97.6 | −0.033 | 0.735 |
| Crystalloid amount, mL | 3491.8 ± 1290.9 | 3301.7 ± 1486.0 | −0.128 | 0.055 | 3370.6 ± 1294.3 | 3397.6 ± 1397.4 | 0.018 | 0.832 |
| Colloid amount, mL | 600.2 ± 460.4 | 519.1 ± 466.0 | −0.174 | 0.016 | 549.0 ± 455.0 | 514.4 ± 476.9 | −0.074 | 0.431 |
| Red blood cell transfusion | 276 (53.3) | 206 (67.8) | 0.309 | < 0.001 | 141 (63.8) | 138 (62.4) | −0.029 | 0.830 |
| Reversal agent of NMB | 0.249 | < 0.001 | 0.024 | 0.890 | ||||
| Neostigmine-glycopyrrolate | 478 (92.3) | 252 (82.9) | 191 (86.4) | 189 (85.5) | ||||
| Sugammadex | 40 (7.7) | 52 (17.1) | 30 (13.6) | 32 (14.5) | ||||
| Urinary diversion type | 0.484 | < 0.001 | −0.027 | 0.847 | ||||
| Ileal conduit | 149 (28.8) | 161 (53.0) | 100 (45.2) | 103 (46.6) | ||||
| Ileal neobladder | 369 (71.2) | 143 (47.0) | 121 (54.8) | 118 (53.4) | ||||
Data are expressed as mean ± standard deviation or number of patients (%), as appropriate
PNI prognostic nutritional index, SMD standardized mean difference, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease, NMB neuromuscular blockade